Should I buy ResMed (RMD) stock or is it too late?
⭐ The most reliable of them, either direction: Jefferies — 72% of its targets hit on this sector (380 calls tested). It aims for $225 (-4.6 %), call made on July 11, 2026, maturing on July 11, 2027 (48 d ago).
Firm-by-firm track record on ResMed
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Mizuho | 56 % | +14.6 % | 9 | $220 -7% |
| UBS | 57 % | +10.8 % | 7 | $325 +38% |
| Citigroup | 40 % | +4.7 % | 5 | $235 +0% |
| RBC Capital | 73 % | +4.1 % | 11 | $244 +3% |
| JP Morgan | 50 % | +3.4 % | 12 | $290 +23% |
| Keybanc | 67 % | +3.1 % | 12 | $255 +8% |
| Oppenheimer | 80 % | +23.9 % | 5 | — |
| B of A Securities | 88 % | +17.1 % | 8 | — |
✅ Reasons to believe
- Few solid positives from analysts right now: of 9 ratings, only 2 buys, and the median price target ($230) is -2% below the price ($236). Caution prevails.
⚠️ Reasons to hesitate
- Even the most reliable firm on RMD, Morgan Stanley (100% hit rate, 4 scored calls), only targets $230 (call made on June 17, 2026, maturing on June 17, 2027) (-2%) in its most recent call, and $304 (call made on October 21, 2025, maturing on October 21, 2026) (+29%) in the one coming due soonest. The stock may already have run past its target.
- The consensus is not unanimous: of 9 ratings, 7 are neutral.
- Limited upside: the median target is only -2% from the current price.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on RMD
Median target $230 (-2%) · 9 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in ResMed now?
We won't decide for you. The facts: 22% of analysts rate it a buy, median target $230 (-2%), and Morgan Stanley (most reliable on RMD, 100%) targets $230. Weigh that against valuation (P/E ~23). This is not personalized advice.
Is it too late to invest in ResMed?
The stated upside is small: the median target ($230) sits just -2% from the price ($236) (most reliable on RMD: Morgan Stanley, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is ResMed still worth investing in?
It depends on the gap between the price ($236) and its estimated value: analysts target $230 on median (-2%), with 22% buys (most reliable on RMD: Morgan Stanley, 100%). Cross-check with their real reliability on RMD and the cautions above. Information, not advice.
What's the main risk in buying RMD?
Even the most reliable firm on RMD, Morgan Stanley (100% hit rate, 4 scored calls), only targets $230 (call made on June 17, 2026, maturing on June 17, 2027) (-2%) in its most recent call, and $304 (call made on October 21, 2025, maturing on October 21, 2026) (+29%) in the one coming due soonest. The stock may already have run past its target.
→ Go deeper: the full ResMed profile (consensus, analyst reliability, price target, performance).